In the high-stakes world of medical technology, clinical evidence has long been viewed through the lens of necessity—a checkbox exercise required to satisfy regulators and gain market access. However, a seismic shift is underway. As global regulations like the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) tighten, and with the impending integration of the EU AI Act and the European Health Data Space (EHDS), the landscape of evidence generation is being fundamentally redefined.
Clinical evidence is no longer merely a regulatory hurdle; it has become a strategic asset. Industry leaders now recognize that the ability to generate high-quality, continuous clinical data is the primary driver of revenue, market differentiation, and long-term business resilience. Yet, despite this realization, many organizations remain hampered by fragmented processes and slow, siloed operational structures. To bridge this gap, industry titans—Smith+Nephew, B. Braun, Philips, and Roche Diagnostics—are pioneering new models that treat evidence generation as a core business function rather than a cost center.
The Regulatory Pressure Cooker: Why Change is Non-Negotiable
The regulatory environment for medtech has evolved from prescriptive to proactive. With the EU MDR and IVDR, the requirements for clinical evaluation reports (CERs) and post-market clinical follow-up (PMCF) have intensified, demanding rigorous, real-world data that proves safety and efficacy throughout the entire product lifecycle.
This regulatory scrutiny is further compounded by the complexity of the digital age. As AI-driven diagnostic tools and software-as-a-medical-device (SaMD) become standard, regulators are demanding transparency in algorithms and data provenance. The European Health Data Space (EHDS) promises to facilitate data sharing, but it also places the burden on manufacturers to prove that their data generation processes are ethical, robust, and reproducible. Companies failing to adapt to this "continuous evidence" model risk more than just market delays—they risk obsolescence.
Core Operational Challenges: The Hidden Friction
Despite the clear strategic intent to prioritize evidence, operational barriers persist across the medtech sector. Fragmented data landscapes, internal departmental silos, and a lack of standardized governance often lead to a "siloed intelligence" problem.
When clinical, commercial, and regulatory teams operate in isolation, study design often suffers from misalignment. A clinical study might be scientifically sound but commercially irrelevant, or conversely, a marketing-driven study might lack the rigor required by notified bodies. This misalignment results in diluted evidence, ballooning costs, and—most critically—significant delays in time-to-market. The industry is currently facing a bottleneck where the speed of innovation far outpaces the speed of evidence generation.
Best Practices from the Field: Lessons from Industry Leaders
To uncover how the industry is overcoming these hurdles, we analyzed the strategic frameworks of four leading organizations. Each has adopted a distinct philosophy for managing clinical evidence.
1. Smith+Nephew: The Power of Governance and Focus
Kolja Boese, MD, Ph.D., head of global medical affairs at Smith+Nephew, identified that the key to efficiency lies in rigorous oversight. By establishing a Clinical Review Committee (CRC) that meets on a monthly basis, the company ensures that every clinical initiative is scrutinized for strategic alignment, progress, and prioritization.
Smith+Nephew’s approach is defined by "primary endpoint discipline." By focusing each study on a single primary endpoint, the company reduces ambiguity and accelerates decision-making. "We found we needed to have a better preparation phase for these studies and have better designs," says Boese. This preparatory rigor not only satisfies notified bodies but also ensures that the outputs are directly applicable to marketing claims and product positioning, effectively turning clinical data into a sales enablement tool.
2. B. Braun: Breaking Down Organizational Silos
For B. Braun, the challenge was communication. Marius Selig, MSc, director of medical scientific affairs at the Aesculap division, noted that clinical data is only as valuable as the team’s ability to use it. His team works to bridge the gap between medical scientific affairs (MSA), marketing, and sales.
Through targeted educational sessions, Selig’s team ensures that commercial teams understand the clinical data, allowing them to leverage medical insights for market differentiation. "If you want to fully leverage medical insights for a medtech company, all the functions need to work together and swim in the same direction," Selig asserts. Looking toward the future, B. Braun is doubling down on automation and AI-driven analytics to translate complex medical data into actionable business intelligence.
3. Philips: Harmonization through Collaboration
Martijn van Steennis, global chief medical officer of diagnostic imaging at Philips, championed the implementation of cross-functional boards to manage the complexity of global evidence generation. These boards serve as a centralized hub where leaders review risks, share updates, and align on evidence priorities.
This structure provides organizational clarity, ensuring that critical stakeholders are involved at the inception of a project rather than at the end. "The advantage is we have more oversight of who’s doing what," van Steennis explains. "We can harmonize all the different types of studies that we do across the world a little bit better." By aligning globally, Philips reduces the risk of redundant studies and ensures that evidence generation is harmonized across diverse regulatory jurisdictions.
4. Roche Diagnostics: Holistic Ownership
Roche Diagnostics has taken a "portfolio lead" approach, which Tilman Rüsike, PhD, lifecycle leader for immunoassays and clinical chemistry, describes as the ultimate solution to fragmentation. By appointing a single individual to own the end-to-end evidence process, the company removes the ambiguity that often arises in matrixed organizations.
This leader acts as a "mini-CEO" for the product portfolio, possessing the authority to make strategic trade-offs between clinical, regulatory, and commercial goals. This holistic ownership ensures that the product’s intended use is precisely defined at the outset, allowing for targeted studies that serve multiple stakeholders simultaneously.
The Future Landscape: Automation and Predictive Insight
The synthesis of these best practices reveals a broader trend: the transition toward a data-driven, automated, and integrated future. The next generation of evidence generation will rely on three key pillars:
- Automation of Routine Processes: AI-powered tools will soon handle the heavy lifting of clinical operations, including drafting protocols and conducting automated literature monitoring for post-market surveillance.
- Predictive Site Selection: Using historical data and benchmarking systems, companies will be able to predict the performance of clinical sites, optimizing resource allocation and reducing the timeline of patient enrollment.
- Integrated Data Ecosystems: The future lies in platforms that integrate clinical, regulatory, and real-world evidence into a single, accessible repository, allowing for real-time decision-making.
Implications: The New Competitive Landscape
As we look toward the next decade, the implications for medtech companies are clear: evidence generation is a business-critical function. The organizations that thrive will be those that view clinical data as a core competency rather than a compliance burden.
Success requires a fundamental change in organizational culture. It necessitates the breakdown of silos, the empowerment of leaders to make end-to-end decisions, and the adoption of technology to accelerate transparency and speed. Companies that successfully bridge the gap between their clinical and commercial ambitions will not only navigate the tightening regulatory landscape with greater ease but will also secure a distinct competitive advantage.
In the modern medtech environment, evidence is the currency of trust. Those who generate it efficiently, communicate it effectively, and leverage it strategically will define the future of global healthcare. As regulatory expectations continue to climb, the industry must stop asking how to meet the minimum standards and start asking how evidence can be used to prove the true value of innovation to patients, providers, and payers alike.
